Predictive oncology and cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence

Eagan, minn., feb. 23, 2023 (globe newswire) -- predictive oncology inc. (nasdaq: poai) and cvergenx, inc. today announced an agreement to form a strategic partnership that has the potential to revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery.
POAI Ratings Summary
POAI Quant Ranking